https://doi.org/10.4081/ejh.2023.3577
The role of miR-143-3p/FNDC1 axis on the progression of non-small cell lung cancer
Submitted: 12 October 2022
Accepted: 22 March 2023
Published: 3 May 2023
Accepted: 22 March 2023
Abstract Views: 649
PDF: 339
HTML: 19
HTML: 19
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The study aimed to explore the functional role of fibronectin type III domain containing 1 (FNDC1) in nonsmall cell lung cancer (NSCLC), as well as the mechanism governing its expression. The expression levels of FNDC1 and related genes in tissue and cell samples were detected by qRT-PCR. Kaplan-Meier analysis was employed to analyze the association between FNDC1 level and the overall survival of NSCLC patients. Functional experiments such as CCK-8 proliferation, colony formation, EDU staining, migration and invasion assays were conducted to investigate the functional role of FNDC1 in regulating the malignancy of NSCLC cells. Bioinformatic tools and dual-luciferase reporter assay were used to identify the miRNA regulator of FNDC1 in NSCLC cells. Our data revealed the upregulation of FNDC1 at mRNA and protein levels in NSCLC tumor tissues cancer cell lines, compared with normal counterparts. NSCLC patients with higher FNDC1 expression suffered from a poorer overall survival. FNDC1 knockdown significantly suppressed the proliferation, migration and invasion of NSCLC cells, and had an inhibitory effect on tube formation. We further demonstrated that miR-143-3p was an upstream regulator of FNDC1 and miR-143-3p expression was repressed in NSCLC samples. Similar to FNDC1 knockdown, miR-143-3p overexpression inhibited the growth, migration and invasion of NSCLC cells. FNDC1 overexpression could partially rescue the effect of miR-143-3p overexpression. FNDC1 silencing also suppressed the tumorigenesis of NSCLC cells in mouse model. In conclusion, FNDC1 promotes the malignant prototypes of NSCLC cells. miR-143-3p is a negative regulator of FNDC1 in NSCLC cells, which may serve as a promising therapeutic target in NSCLC.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
DOI: https://doi.org/10.3322/caac.21492
Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res 2016;5:288-300.
DOI: https://doi.org/10.21037/tlcr.2016.06.07
Dias M, Linhas R, Campainha S, Conde S, Barroso A. Lung cancer in never-smokers–what are the differences? Acta Oncologica 2017;56:931-5.
DOI: https://doi.org/10.1080/0284186X.2017.1287944
Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - A different disease. Nat Rev Cancer 2007;7:778-90.
DOI: https://doi.org/10.1038/nrc2190
Lemjabbar-Alaoui H, Hassan OUI, Yang YW, Buchanan P. Lung cancer: biology and treatment options. Biochim Biophys Acta Rev Cancer 2015;1856:189-210.
DOI: https://doi.org/10.1016/j.bbcan.2015.08.002
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 2019;28:1563-79.
DOI: https://doi.org/10.1158/1055-9965.EPI-19-0221
Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009;15:5359-68.
DOI: https://doi.org/10.1158/1078-0432.CCR-09-0033
Wang DC, Wang W, Zhu B, Wang X. Lung cancer heterogeneity and new strategies for drug therapy. Annu Rev Pharmacol Toxicol 2018;58:531-46.
DOI: https://doi.org/10.1146/annurev-pharmtox-010716-104523
Lin TC, Yang CH, Cheng LH, Chang WT, Lin YR, Cheng HC. Fibronectin in cancer: friend or foe. Cells 2020;9:27.
DOI: https://doi.org/10.3390/cells9010027
Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002;115:3861-3.
DOI: https://doi.org/10.1242/jcs.00059
Albrecht M, Renneberg H, Möschler O, Janssen M, Aumüller G, Konrad L, et al. Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance. Histochem Cell Biol 1999;112:51-61.
DOI: https://doi.org/10.1007/s004180050391
Fernandez-Garcia B, Eiró N, Marín L, González-Reyes S, González LO, Lamelas ML, et al. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 2014;64:512-22.
DOI: https://doi.org/10.1111/his.12300
Anderegg U, Breitschwerdt K, Köhler MJ, Sticherling M, Haustein UF, Simon JC, et al. MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-β and pro-inflammatory cytokines. Exp Dermatol 2005;14:709-18.
DOI: https://doi.org/10.1111/j.0906-6705.2005.00349.x
Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, et al. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Exp Cell Res 2016;348:190-200.
DOI: https://doi.org/10.1016/j.yexcr.2016.09.021
Jiang T, Gao W, Lin S, Chen H, Du B, Liu Q, et al. FNDC1 Promotes the invasiveness of gastric cancer via Wnt/β-catenin signaling pathway and correlates with peritoneal metastasis and prognosis. Front Oncol 2020;10:590492.
DOI: https://doi.org/10.3389/fonc.2020.590492
Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta 2019;491:39-45.
DOI: https://doi.org/10.1016/j.cca.2019.01.011
Liu YP, Chen WD, Li WN, Zhang M. Overexpression of FNDC1 relates to poor prognosis and its knockdown impairs cell invasion and migration in gastric cancer. Technol Cancer Res Treat 2019;18:153303381986992.
DOI: https://doi.org/10.1177/1533033819869928
Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, et al. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Letters 2015;363:17-27.
DOI: https://doi.org/10.1016/j.canlet.2015.03.026
Bell A, Bell D, Weber RS, El-Naggar AK. CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer 2011;117:2898-909.
DOI: https://doi.org/10.1002/cncr.25818
Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014;9:287-314.
DOI: https://doi.org/10.1146/annurev-pathol-012513-104715
Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, et al. MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol 2009;181:1372-80.
DOI: https://doi.org/10.1016/j.juro.2008.10.149
Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, et al. MiR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep 2012;5:753-60.
Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, et al. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol 2013;19:7758-65.
DOI: https://doi.org/10.3748/wjg.v19.i43.7758
Ethics Approval
the study was approved by the Ethics Committee Board of Affiliated Hospital of Chifeng University, All animal procedures were approved by the Animal Care and Use Ethical Committee of Affiliated Hospital of Chifeng UniversityHow to Cite
Ma, Z., Gao, Q., Xin, W., Wang, L., Chen, Y., Su, C., … Sun, R. (2023). The role of miR-143-3p/FNDC1 axis on the progression of non-small cell lung cancer. European Journal of Histochemistry, 67(2). https://doi.org/10.4081/ejh.2023.3577
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Nuobei Zhang, Hao Shen, Shenan Huang, Fenfen Wang, Huifang Liu, Fen Xie, Lei Jiang, Xin Chen, LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma , European Journal of Histochemistry: Vol. 65 No. 4 (2021)
- Michael W.L. Quirino, Amanda P.B. Albuquerque, Maria F.D. de Souza, Antônio F. da Silva Filho, Mário R. Martins, Maira G. da Rocha Pitta, Michelly C. Pereira, Moacyr J.B. de Melo Rêgo, alpha2,3 sialic acid processing enzymes expression in gastric cancer tissues reveals that ST3Gal3 but not Neu3 are associated with Lauren's classification, angiolymphatic invasion and histological grade , European Journal of Histochemistry: Vol. 66 No. 4 (2022)
- C. Bai, D. Wang, C. Li, D. Jin, C. Li, W. Guan, Y. Ma, Establishment and biological characteristics of a Jingning chicken embryonic fibroblast bank , European Journal of Histochemistry: Vol. 55 No. 1 (2011)
- Xiong Bing Li, Jia Li Li, Chao Wang, Yong Zhang, Jing Li, Identification of mechanism of the oncogenic role of FGFR1 in papillary thyroid carcinoma , European Journal of Histochemistry: Vol. 68 No. 3 (2024)
- Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito, Naohiro Oka, Ryosuke Kakinoki, Masao Akagi, Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma , European Journal of Histochemistry: Vol. 66 No. 3 (2022)
- Qian Hu, Ran Tao, Xiaoyun Hu, Haibo Wu, Jianjun Xu, Effects of piperlonguminine on lung injury in severe acute pancreatitis via the TLR4/NF-κB pathway , European Journal of Histochemistry: Vol. 67 No. 2 (2023)
- E. Carabajal, N. Massari, M. Croci, D. J. Martinel Lamas, J. P. Prestifilippo, R. M. Bergoc, E. S. Rivera, V. A. Medina, Radioprotective potential of histamine on rat small intestine and uterus , European Journal of Histochemistry: Vol. 56 No. 4 (2012)
- Y. Asara, J. A. Marchal, P. Bandiera, V. Mazzarello, L. G. Delogu, M. A. Sotgiu, A. Montella, R. Madeddu, Cadmium influences the 5-Fluorouracil cytotoxic effects on breast cancer cells , European Journal of Histochemistry: Vol. 56 No. 1 (2012)
- P. Donizy, A. Halon, P. Surowiak, G. Pietrzyk, C. Kozyra, R. Matkowski, Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells , European Journal of Histochemistry: Vol. 57 No. 4 (2013)
- A.M. Schläfli, S. Berezowska, O. Adams, R. Langer, M.P. Tschan, Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry , European Journal of Histochemistry: Vol. 59 No. 2 (2015)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
